Cell BiologybioRxivPreprint
Selective LXR agonist, DMHCA, corrects the retina-bone marrow axis in type 2 diabetes
C. P. Vieira, S. D. Fortmann, M. Hossain…·M. B. Grant
This study shows that DMHCA, a selective LXR agonist, corrects the retina-bone marrow axis in type 2 diabetes by restoring retinal function, cholesterol homeostasis, and hematopoietic stem cell balance.